It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
scientific solutions | protein science & structural biology
Protein Purification
Delivering high-quality, functional proteins with tailored purification strategies to meet your end use requirements. Enabling confident data driven decisions and faster progress.
Whether you’re running biochemical assays, structural studies, or therapeutic discovery, we ensure your proteins arrive in the right form and quantity.
Our workflows are built around your target’s unique requirements, with expertise spanning soluble and membrane proteins, large complexes, and challenging constructs. Every project benefits from our adaptive, data-driven approach designed to deliver proteins that are stable, active, and ready to move your science forward.
How we can assist you
We take a data-driven, adaptable approach that considers both your end-use requirements and the biophysical properties of your target. This ensures the proteins we produce meet your specifications for purity, homogeneity, activity, and stability, resulting in reliable, reproducible proteins that support confident decisions in your program.
Protein Purification & Downstream Handling
Construct design :
We evaluate protein domains and structure along with considering the end-use and purification strategy.
Chromatography methods :
We apply both standard and bespoke techniques to achieve high-grade purification.
Membrane protein expertise:
Our dedicated team specialized in purifying challenging membrane proteins.
Protein refolding:
We recover functional proteins from inclusion bodies when needed.
Intracellular biotinylation:
We offer biotinylation during translation for specific applications.
Low endotoxin production:
Available when required for sensitive downstream use.
Quality Control & Characterization
Every protein we deliver undergoes rigorous quality control to ensure it is fit for purpose. Standard methods include SDS-PAGE, analytical SEC, A280 measurements, and intact mass spectrometry. For deeper insights, our biophysics team supports characterization with binding and stability assays such as SPR, DLS, MST, FTSA, and CET SA. Depending on your project, we can also perform peptide mapping by LC-MS, endotoxin testing and apply advanced techniques like SEC-MALS, FSEC, or FIDA.
Hear From One of our Experts
Protein Science is the largest of our teams within the Protein & Structure department at Sygnature Discovery, and between us we have tackled the purification and analysis of many diverse protein targets. The more challenging, the better… If there is a solution to a protein problem to be found, we will move mountains to find it.
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
At Sygnature we have a dedicated Protein Expression team with expertise across various E. coli, insect cells and mammalian (HEK and CHO) host cell lines.
We provide advanced biophysical techniques for protein identity, quality, and stability. Including mass spectrometry, FIDA, and NMR tailored to your research needs.
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
![Sygnature TL1A [C95S/C135S] Structure](data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iNDAwIiBoZWlnaHQ9IjM1OSIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj48cmVjdCB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBmaWxsPSIjZjNmNGY2Ii8+PC9zdmc+)
![Sygnature TL1A [C95S/C135S] Structure](https://www.sygnaturediscovery.com/wp-content/uploads/2025/12/Sygnature-TL1A-Structure-400x359-1.webp)
